Kava is not an opioid. It belongs to a completely different chemical class, produces its effects through different brain pathways, and carries a fundamentally different risk profile. The confusion likely stems from the fact that kava can produce relaxation, mild euphoria, and even some pain relief, effects that people associate with opioids. But the similarities end at the surface.
How Kava Actually Works in the Brain
Opioids work by binding tightly to mu-opioid receptors, the same receptors your body’s natural painkillers (endorphins) use. This is what produces their powerful pain relief, their intense euphoria, and their high potential for addiction and fatal overdose. Kava takes an entirely different route.
The active compounds in kava, called kavalactones, primarily enhance the activity of GABA-A receptors, the brain’s main “calm down” signaling system. This is the same general system that benzodiazepines and alcohol act on, though kavalactones interact with a different binding site than benzodiazepines do. Research published in the Journal of Pharmacology and Experimental Therapeutics found that kavain, the most abundant kavalactone, positively modulates GABA-A receptors in a concentration-dependent way, producing moderate enhancement of the brain’s natural calming signals.
Beyond GABA, kavalactones also reduce neuronal excitability by blocking sodium and calcium channels on nerve endings, reversibly inhibit an enzyme called MAO-B (which breaks down certain mood-related brain chemicals), and lower levels of excitatory amino acids in the hippocampus and striatum. The net result is relaxation, reduced anxiety, and mild sedation, without the respiratory depression that makes opioids deadly in overdose.
Kava Does Interact With Opioid Receptors, Slightly
One reason this question keeps coming up is that lab studies have found kava extracts can bind to mu and delta opioid receptors in test-tube experiments. A study testing Hawaiian kava cultivars found that leaf extracts inhibited binding at opioid receptors with moderate potency, while root extracts (the part traditionally consumed) showed much weaker binding, requiring concentrations at or above 100 micrograms per milliliter to have an effect.
This is a far cry from how actual opioids work. Morphine and fentanyl bind to opioid receptors with extreme selectivity and potency. Kava’s opioid receptor activity is weak, likely not the primary driver of its effects, and has not been shown to produce the hallmark opioid responses (respiratory depression, constipation, or the characteristic “high”) in humans at normal doses. The fact that a substance touches a receptor in a lab dish doesn’t make it an opioid any more than eating a poppy seed bagel makes you a heroin user.
Kava’s Pain-Relieving Effects Don’t Use Opioid Pathways
Kava does have genuine analgesic properties, which may further fuel the comparison. Four kavalactones (kavain, dihydrokavain, methysticin, and dihydromethysticin) have shown significant pain-relieving effects in animal studies. Kavain in particular has been found to be comparable to cocaine as a local surface anesthetic in terms of strength and duration.
But researchers have specifically tested whether this pain relief works through the opioid system, and it doesn’t. Studies on kavain-like compounds found potent, dose-dependent analgesic activity that could be blocked by standard pain pathway tests but was not reversed by opioid-blocking drugs. The mechanism remains somewhat uncertain, but the evidence points clearly to non-opioid pathways.
Dependence Risk Is Much Lower Than Opioids
Opioid use disorder develops in roughly 8 to 12 percent of people prescribed opioids for chronic pain, and withdrawal can be severe and prolonged. Kava’s dependence profile looks very different. A study assessing past-year kava users found that only 7.5 percent met criteria for a kava use disorder, and most of those cases were mild. The most commonly reported issues were using more kava than intended (7.5 percent of users) and experiencing cravings (6 percent).
Physical or psychological withdrawal symptoms after stopping kava were reported by just 3.7 percent of past-year users, and only 3 percent reported continuing to use kava specifically to avoid withdrawal. Among people who tried to quit, nearly 90 percent succeeded. Those who didn’t cited difficulties managing mild withdrawal symptoms or simply missing the ritual. This is a substantially different picture from opioid dependence, where withdrawal is often described as one of the most physically miserable experiences a person can endure.
Mixing Kava With Opioids Is Dangerous
While kava isn’t an opioid, combining it with opioids or other central nervous system depressants is genuinely risky. Kavalactones have a synergistic sedative effect when combined with other GABA-active substances. One case report documented a 54-year-old man hospitalized in a semicomatose state after a possible interaction between kava and a benzodiazepine. Animal studies have shown that alcohol markedly enhances kava’s toxicity, with each substance amplifying the other’s sedative effects.
The mechanism behind these interactions involves kava’s ability to inhibit liver enzymes (CYP450 isozymes) that metabolize many prescription drugs. If you’re taking opioids, benzodiazepines, or other sedating medications, kava can slow their breakdown, leading to elevated and potentially toxic concentrations in your bloodstream. This enzyme inhibition is also central to kava’s most serious standalone safety concern: liver damage.
The Liver Safety Question
In 2002, the FDA issued an advisory warning that kava-containing dietary supplements may be associated with severe liver injury, including hepatitis, cirrhosis, liver failure, and at least one case requiring a liver transplant in a previously healthy young woman. Over 25 reports of liver-related injuries had been documented internationally at that time. The risk appears to be higher with concentrated extract supplements than with traditionally prepared kava beverages, though the exact reasons remain debated. Factors like pre-existing liver conditions, alcohol use, and concurrent medications likely increase vulnerability.
This is another area where kava and opioids differ sharply. Opioids carry risks of respiratory depression and overdose death. Kava’s primary organ-level risk is hepatic, not respiratory. They’re different substances with different dangers, and treating them as interchangeable because they both produce relaxation leads to poor decision-making in both directions.